GENPREX INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
GENPREX INC. - More news...
GENPREX INC. - More news...
- Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
- Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
- Genprex to Present at NobleCon17 on January 19
- Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
- Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
- Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants
- Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer
- Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
- Genprex to Present at the Benzinga Global Small Cap Conference on December 8
- Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
- Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1
- Genprex to Participate in Panel at Life Sciences Summit on November 17
- Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD
- Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer
- Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
- Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing
- Genprex to Present at Zooming with LD Micro on October 14, 2020
- Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
- Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
- Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs
- Genprex to Present at The LD 500 Virtual Conference
- Genprex to Present at The LD 500 Virtual Conference
- Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020
- Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”
- National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex
- Genprex Added to Russell 3000® Index
- Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
- Genprex CEO to Interview Live on “The Big Biz Show”
- Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development
- Genprex Scheduled to Join Russell 3000® Index
